{
  "citations" : [ {
    "@id" : "https://pharmgkb.org/literature/15065128",
    "@context" : "https://api.pharmgkb.org/jsonld/literature.jsonld",
    "id" : 15065128,
    "resourceId" : "23024028",
    "title" : "2012 American College of Rheumatology guidelines for management of gout. Part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia.",
    "_sameAs" : "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3683400",
    "authors" : [ "Khanna Dinesh", "Fitzgerald John D", "Khanna Puja P", "Bae Sangmee", "Singh Manjit K", "Neogi Tuhina", "Pillinger Michael H", "Merill Joan", "Lee Susan", "Prakash Shraddha", "Kaldas Marian", "Gogia Maneesh", "Perez-Ruiz Fernando", "Taylor Will", "Lioté Frédéric", "Choi Hyon", "Singh Jasvinder A", "Dalbeth Nicola", "Kaplan Sanford", "Niyyar Vandana", "Jones Danielle", "Yarows Steven A", "Roessler Blake", "Kerr Gail", "King Charles", "Levy Gerald", "Furst Daniel E", "Edwards N Lawrence", "Mandell Brian", "Schumacher H Ralph", "Robbins Mark", "Wenger Neil", "Terkeltaub Robert", "American College of Rheumatology" ],
    "hasKeyword" : false,
    "journal" : "Arthritis care & research",
    "meshDiseases" : [ "PA166048814", "PA444318" ],
    "meshTerms" : [ "Gout", "Gout Suppressants", "Humans", "Hyperuricemia", "Rheumatology" ],
    "month" : 10,
    "nonHuman" : false,
    "objCls" : "Literature",
    "page" : "1431-46",
    "pgkbPublication" : false,
    "pubDate" : "2012-10-01T00:00:00-07:00",
    "type" : "Article",
    "version" : 4,
    "volume" : "64",
    "xrefs" : [ {"@id":"https://pharmgkb.org/crossReference/pmc/PMC3683400","@context":"https://api.pharmgkb.org/jsonld/crossReference.jsonld","id":1449278170,"resource":"PubMed Central","resourceId":"PMC3683400","_url":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3683400"}, {"@id":"https://pharmgkb.org/crossReference/pubMed/23024028","@context":"https://api.pharmgkb.org/jsonld/crossReference.jsonld","id":1449278169,"resource":"PubMed","resourceId":"23024028","_url":"https://www.ncbi.nlm.nih.gov/pubmed/23024028"}, {"@id":"https://pharmgkb.org/crossReference/doi/10.1002/acr.21772","@context":"https://api.pharmgkb.org/jsonld/crossReference.jsonld","id":1449278171,"resource":"DOI","resourceId":"10.1002/acr.21772","_url":"http://dx.doi.org/10.1002%2Facr.21772"} ],
    "year" : 2012
  } ],
  "guideline" : {
    "@id" : "https://pharmgkb.org/guidelineAnnotation/PA166104993",
    "@context" : "https://api.pharmgkb.org/jsonld/guidelineAnnotation.jsonld",
    "objCls" : "Guideline Annotation",
    "id" : "PA166104993",
    "name" : "Annotation of PRO Guideline for allopurinol and HLA-B",
    "cancerGenome" : false,
    "guidelineGenes" : [ ],
    "history" : [ {
      "id" : 1183704559,
      "date" : "2012-10-01T00:00:00-07:00",
      "type" : "Create",
      "version" : 0
    } ],
    "literature" : [ {"@id":"https://pharmgkb.org/literature/15065128","@context":"https://api.pharmgkb.org/jsonld/literature.jsonld","id":15065128,"resourceId":"23024028","title":"2012 American College of Rheumatology guidelines for management of gout. Part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia.","_sameAs":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3683400","objCls":"Literature","type":"Article","xrefs":[{"@id":"https://pharmgkb.org/crossReference/pmc/PMC3683400","@context":"https://api.pharmgkb.org/jsonld/crossReference.jsonld","id":1449278170,"resource":"PubMed Central","resourceId":"PMC3683400","_url":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3683400"},{"@id":"https://pharmgkb.org/crossReference/pubMed/23024028","@context":"https://api.pharmgkb.org/jsonld/crossReference.jsonld","id":1449278169,"resource":"PubMed","resourceId":"23024028","_url":"https://www.ncbi.nlm.nih.gov/pubmed/23024028"},{"@id":"https://pharmgkb.org/crossReference/doi/10.1002/acr.21772","@context":"https://api.pharmgkb.org/jsonld/crossReference.jsonld","id":1449278171,"resource":"DOI","resourceId":"10.1002/acr.21772","_url":"http://dx.doi.org/10.1002%2Facr.21772"}]} ],
    "recommendation" : true,
    "relatedAlleles" : [ ],
    "relatedChemicals" : [ {
      "@id" : "https://pharmgkb.org/chemical/PA448320",
      "@context" : "https://api.pharmgkb.org/jsonld/chemical.jsonld",
      "objCls" : "Chemical",
      "id" : "PA448320",
      "name" : "allopurinol",
      "version" : 6
    } ],
    "relatedGenes" : [ {
      "@id" : "https://pharmgkb.org/gene/PA35056",
      "@context" : "https://api.pharmgkb.org/jsonld/gene.jsonld",
      "objCls" : "Gene",
      "id" : "PA35056",
      "symbol" : "HLA-B",
      "name" : "major histocompatibility complex, class I, B",
      "version" : 40
    } ],
    "source" : "Professional Society",
    "summaryMarkdown" : {
      "id" : 1447982018,
      "html" : "<p>HLA-B*58:01-positive individuals (those with the HLA-B*58:01 variant allele) should be prescribed an alternative drug to allopurinol.</p>\n",
      "version" : 1
    },
    "terms" : [ ],
    "textMarkdown" : {
      "id" : 1447982017,
      "html" : "<p>The <strong>American College of Rheumatology</strong> guidelines for the management of gout include the following statement about pharmacogenomic testing for HLA-B*58:01 and allopurinol:</p>\n<blockquote class=\"blockquote\">\n<p>Those with HLA-B*5801 and of Korean descent with stage 3 or worse CKD (HLA-B*5801 allele frequency ~12%), or of Han Chinese or Thai extraction irrespective of renal function (HLA-B*5801 allele frequency ~6-8%), have been highlighted in the literature as prime examples of subjects at high risk for AHS, marked by HLA-B*5801 hazard ratios of several hundred.  Such high-risk individuals were recommended to be prescribed an alternative to allopurinol if HLA-B*5801 positive.</p>\n</blockquote>\n<p>excerpted from <a href=\"https://api.pharmgkb.org/v1/download/file/attachment/GuidelinesHLABallopurinolACR.pdf\">2012 American College of Rheumatology Guidelines for the Management of Gout. Part1</a></p>\n",
      "version" : 7
    },
    "userId" : "whaleyr",
    "version" : 16,
    "xrefs" : [ ]
  }
}